630 related articles for article (PubMed ID: 16553572)
1. The pharmacological treatment of primary aldosteronism.
Janmohamed S; Bouloux PM
Expert Opin Pharmacother; 2006 Apr; 7(5):563-73. PubMed ID: 16553572
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological treatment of aldosterone excess.
Deinum J; Riksen NP; Lenders JW
Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid antagonism and cardiac hypertrophy.
Nagata K
Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
[TBL] [Abstract][Full Text] [Related]
4. A review of the medical treatment of primary aldosteronism.
Lim PO; Young WF; MacDonald TM
J Hypertens; 2001 Mar; 19(3):353-61. PubMed ID: 11288803
[TBL] [Abstract][Full Text] [Related]
5. Primary aldosteronism in pregnancy.
Krysiak R; Samborek M; Stojko R
Acta Clin Belg; 2012; 67(2):130-4. PubMed ID: 22712170
[TBL] [Abstract][Full Text] [Related]
6. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
Young MJ; Funder JW
J Hypertens; 2002 Aug; 20(8):1465-8. PubMed ID: 12172301
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of drug-based and surgical treatments for primary aldosteronism.
Steichen O; Lorthioir A; Zinzindohoue F; Plouin PF; Amar L
Adv Chronic Kidney Dis; 2015 May; 22(3):196-203. PubMed ID: 25908468
[TBL] [Abstract][Full Text] [Related]
11. Effect of the interaction between the visceral-to-subcutaneous fat ratio and aldosterone on cardiac function in patients with primary aldosteronism.
Haze T; Ozawa M; Kawano R; Haruna A; Ohki Y; Suzuki S; Kobayashi Y; Fujiwara A; Saka S; Tamura K; Hirawa N
Hypertens Res; 2023 May; 46(5):1132-1144. PubMed ID: 36754972
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
[TBL] [Abstract][Full Text] [Related]
13. High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients.
Stowasser M; Gordon RD; Gunasekera TG; Cowley DC; Ward G; Archibald C; Smithers BM
J Hypertens; 2003 Nov; 21(11):2149-57. PubMed ID: 14597859
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
15. Update in primary aldosteronism.
Stowasser M
J Clin Endocrinol Metab; 2009 Oct; 94(10):3623-30. PubMed ID: 19737921
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor signalling in primary aldosteronism.
Yang J; Young MJ; Cole TJ; Fuller PJ
J Endocrinol; 2023 Sep; 259(1):. PubMed ID: 37486000
[TBL] [Abstract][Full Text] [Related]
17. Diagnosing and Managing Primary Aldosteronism in Hypertensive Patients: a Case-Based Approach.
Carey RM
Curr Cardiol Rep; 2016 Oct; 18(10):97. PubMed ID: 27566330
[TBL] [Abstract][Full Text] [Related]
18. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
Colussi G; Catena C; Sechi LA
J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Stavropoulos K; Papadopoulos C; Koutsampasopoulos K; Lales G; Mitas C; Doumas M
Curr Pharm Des; 2018; 24(46):5508-5516. PubMed ID: 30854950
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone receptor antagonists: current perspectives and therapies.
Guichard JL; Clark D; Calhoun DA; Ahmed MI
Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
